Insight Molecular Diagnostics will report Q2 2025 financial results on August 11, 2025, followed by a webinar.
Quiver AI Summary
Insight Molecular Diagnostics (iMDx) announced it will release its second quarter 2025 financial results on August 11, 2025, after market close, followed by a live Zoom webinar at 2:00 PM PT/5:00 PM ET to discuss the results and answer questions from investors. An archived version of the webinar will be available on the company's investor relations website. Additionally, on August 12, CEO Josh Riggs and CFO Andrea James will participate in the 10th Annual Needham Virtual MedTech & Diagnostics Conference, where investors can schedule individual meetings with management. iMDx, which recently relocated its headquarters to Nashville, Tenn., aims to enhance access to molecular diagnostic testing to improve patient outcomes.
Potential Positives
- iMDx will be reporting its second quarter 2025 financial results, which provides transparency to investors and stakeholders about the company's performance.
- The live webinar following the financial results allows for direct engagement with stakeholders, fostering a sense of community and transparency.
- Participation in the 10th Annual Needham Virtual MedTech & Diagnostics Conference highlights iMDx's commitment to industry presence and networking with investors.
- The rebranding from Oncocyte Corp. to Insight Molecular Diagnostics signifies a strategic shift and focus on novel molecular diagnostic testing, enhancing its market positioning.
Potential Negatives
- The announcement does not provide any information on the financial performance or expectations for the upcoming quarter, which may raise concerns among investors about potential financial transparency.
- The company has recently undergone a name change and headquarters relocation, which could imply instability or difficulties in transitioning for stakeholders.
- There is no mention of any new products or innovations in the press release, potentially indicating a lack of growth or advancements within the company.
FAQ
When will iMDx report its second quarter 2025 financial results?
iMDx will report its second quarter 2025 financial results after market close on August 11, 2025.
How can I attend the iMDx financial results webinar?
The webinar can be attended by registering at the iMDX Q2 2025 Earnings Webinar link provided in the press release.
What is the date of the Needham Virtual MedTech & Diagnostics Conference?
The 10th Annual Needham Virtual MedTech & Diagnostics Conference will take place on August 12, 2025.
Who will represent iMDx at the Needham Conference?
iMDx will be represented by CEO Josh Riggs and CFO Andrea James at the Needham Conference.
Where can I find more information about iMDx’s financial performance?
More information about iMDx’s financial performance can be found on their investor relations website at https://investors.imdxinc.com/.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q2 2025 Earnings Webinar .
An archived replay will be available after the call concludes on iMDX’s investor relations website at https://investors.imdxinc.com/ .
10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Separately, on August 12 th , Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference, taking place from August 11-12, 2025.
Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Needham sales representative.
Event:
10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Dates:
August 12, 2025
Location:
Virtual
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.
iMDx™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
[email protected]
